Liana Gercheva

3.2k total citations
46 papers, 1.3k citations indexed

About

Liana Gercheva is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Liana Gercheva has authored 46 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 23 papers in Hematology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Liana Gercheva's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Lymphoma Diagnosis and Treatment (14 papers). Liana Gercheva is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Lymphoma Diagnosis and Treatment (14 papers). Liana Gercheva collaborates with scholars based in Bulgaria, Austria and Poland. Liana Gercheva's co-authors include Vesselina Goranova‐Marinova, Toshko Lissitchkov, Ali Aldaoud, Wolfgang Knauf, Raoul Herbrecht, Peter Klein, Marco Montillo, Martin Becker, Françoise Huguet and K Merkle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Liana Gercheva

43 papers receiving 1.2k citations

Peers

Countries citing papers authored by Liana Gercheva

Since Specialization

Citations

This map shows the geographic impact of Liana Gercheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liana Gercheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liana Gercheva more than expected).

Fields of papers citing papers by Liana Gercheva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liana Gercheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liana Gercheva. The network helps show where Liana Gercheva may publish in the future.

Co-authorship network of co-authors of Liana Gercheva

This figure shows the co-authorship network connecting the top 25 collaborators of Liana Gercheva. A scholar is included among the top collaborators of Liana Gercheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liana Gercheva. Liana Gercheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort 2021 ·Journal of Thrombosis and Haemostasis ·John Pasi, Toshko Lissitchkov, Vasily Mamonov, Tim Mant, Margarita Timofeeva, Catherine Bagot, Pratima Chowdary, Pencho Georgiev, Liana Gercheva, (unknown), Nguyễn Văn Huy, Qifeng Yu, Baisong Mei, Craig C Benson, Margaret V. Ragni	69
2	Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia 2020 ·Cardiovascular Toxicology ·Mirjana Gotić, Miklós Egyed, Liana Gercheva, Krzysztof Warzocha, Hans Michael Kvasnicka, (unknown), Jingyang Wu	4
3	Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria 2019 ·Indian Journal of Hematology and Blood Transfusion ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Liana Gercheva	1
4	INVESTIGATION OF IMMUNOSUPPRESSED PATIENTS FOR THE PRESENCE OF EBV DNA IN REAL TIME PCR 2018 ·Journal of IMAB - Annual Proceeding (Scientific Papers) ·(unknown), (unknown), (unknown), (unknown), Liana Gercheva, (unknown), (unknown)	1
5	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS 2018 ·Leukemia ·Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, Aristoteles Giagounidis, Rudolf Schlag, Atanas Radinoff, Liana Gercheva, Αchilles Anagnostopoulos, Esther Natalie Olíva, Argiris Symeonidis, (unknown), Katharina S. Götze, Anna Potamianou, (unknown), Robert Wapenaar, (unknown), Uwe Platzbecker	99
6	Effect of late prophylaxis in hemophilia on joint status: a randomized trial 2017 ·Journal of Thrombosis and Haemostasis ·Marilyn J. Manco‐Johnson, Björn Lundin, Sharon Funk, Charles Peterfy, David Raunig, Michael Werk, Christine L. Kempton, Mark T. Reding, Vesselina Goranova‐Marinova, Liana Gercheva, L. Rusen, Valentina Uscătescu, (unknown), Steven Engelen, Jennifer Pocoski, (unknown), (unknown)	87
7	CHRONIC MYELOMONOCYTIC LEUKEMIA - REVIEW AND CLINICAL EXPERIENCE OF THE HEMATOLOGY DEPARTMENT UMHAT "ST. MARINA" - VARNA 2016 ·Journal of IMAB - Annual Proceeding (Scientific Papers) ·(unknown), Trifon Chervenkov, (unknown), Liana Gercheva	0
8	Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study) 2015 ·Thrombosis Research ·Aleksander B. Skotnicki, Toshko Lissitchkov, Vasily Mamonov, (unknown), Kazimierz Kuliczkowski, Vesselina Goranova‐Marinova, Janusz Kłoczko, Anna Klukowska, (unknown), Liana Gercheva, Tatiana A. Chernova, Andrzej Hellmann, Anna Dmoszyńska, Krystyna Zawilska, Alex Veldman, (unknown), Wilfried Seifert	6
9	A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma 2014 ·American Journal of Hematology ·Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather J. Sutherland, Tadeusz Robak, Tamás Masszi, Vesselina Goranova‐Marinova, Meletios Α. Dimopoulos, James D. Cavenagh, Ivan Špıčka, Ângelo Maiolino, А. Н. Суворов, Joan Bladé, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, (unknown)	115
10	CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 2014 ·Journal of IMAB - Annual Proceeding (Scientific Papers) ·Liana Gercheva, (unknown), (unknown), (unknown), (unknown), (unknown)	0
11	Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) 2013 ·Journal of Thrombosis and Haemostasis ·Marilyn J. Manco‐Johnson, Christine L. Kempton, Mark T. Reding, Toshko Lissitchkov, Vesselina Goranova‐Marinova, Liana Gercheva, L. Rusen, (unknown), Valentina Uscătescu, (unknown), (unknown)	149
12	High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial 2012 ·Haematologica ·Andreas Petzer, Dominic Fong, Thomas Lion, Iryna Dyagil, (unknown), Andrija Bogdanović, Laimonas Griškevičius, Sandra Lejniece, Vesselina Goranova‐Marinova, Liana Gercheva, Dražen Stojanović, (unknown), Nikolay Tzvetkov, (unknown), (unknown), Thomas Grubinger, (unknown), (unknown), Günther Gastl, Dominik Wolf‎	9
13	Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial 2011 ·The Lancet Oncology ·Thomas Elter, Liana Gercheva, (unknown), Tadeusz Robak, Branimir Jakšić, Grigoriy Rekhtman, Sławomira Kyrcz‐Krzemień, M. T. Vatutin, Jingyang Wu, Cynthia A. Sirard, Michael Hallek, Andreas Engert	64
14	A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia B 2011 ·Haemophilia ·Toshko Lissitchkov, Michał Matysiak, (unknown), Paweł Łaguna, Liana Gercheva, (unknown), (unknown), José A. Aznar, (unknown), Antonio Páez	17
15	High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study 2010 ·Haematologica ·Andreas Petzer, Dominik Wolf‎, Dominic Fong, Thomas Lion, Iryna Dyagil, Zvenyslava Masliak, Andrija Bogdanović, Laimonas Griškevičius, Sandra Lejniece, Vesselina Goranova‐Marinova, Liana Gercheva, Dražen Stojanović, (unknown), Nikolay Tzvetkov, (unknown), (unknown), Hanno Ulmer, (unknown), (unknown), Günther Gastl	27
16	Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia 2010 ·Blood ·Wolfgang Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna Marina Liberati, Javier Loscertales, Raoul Herbrecht, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Vesselina Goranova‐Marinova, Martin Becker, (unknown), Françoise Huguet, (unknown), Peter Klein, K Merkle, Marco Montillo	10
17	Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study 2009 ·Lund University Publications (Lund University) ·(unknown), (unknown), (unknown), Raoul Herbrecht, A.M. Liberati, Javier Loscertales, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Vesselina Goranova‐Marinova, Martin Becker, Klaus Hoeffken, Françoise Huguet, R. Foà, K Merkle, Marco Montillo	1
18	Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols^®) with a 6‐month follow up in previously treated patients with severe haemophilia B 2009 ·Haemophilia ·José A. Aznar, (unknown), Michał Matysiak, Krystyna Zawilska, Liana Gercheva, (unknown), (unknown), Antonio Páez, Toshko Lissitchkov	11
19	Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia 2008 ·Scandinavian Journal of Clinical and Laboratory Investigation ·(unknown), Anton B. Tonchev, (unknown), (unknown), Liana Gercheva	15
20	Cytostatic therapy and blood antioxidants/prooxidants balance in acute myeloblastic leukemia patients 2006 ·Open Medicine ·Daniela Gerova, (unknown), T. Yankova, Liana Gercheva, Diana Ivanova	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact